Hualan Biological EngineeringInc (002007) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Hualan Biological Engineering Inc., together with its subsidiaries, engages in the research, development, production, and sale of biological products in China and internationally.
Total Assets Chart for Hualan Biological EngineeringInc
Hualan Biological EngineeringInc (002007) total assets for FY2025 were CNY 15.3B, a -6.4% change from FY2024. Hualan Biological EngineeringInc's total assets grew from CNY 195.1M in 2001 to CNY 15.3B in 2025 (7722.2% over 24 years). Total assets compound annual growth rate: 5-year CAGR of 8.7%, 10-year CAGR of 14.3%, 20-year CAGR of 16.7%.
Total Assets (CNY)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- ¥23.81B
- Implied Share Price
- ¥13.04
- Enterprise Value
- ¥21.06B
- Revenue (TTM)
- ¥4.36B
- EBITDA
- ¥1.23B
- Profit Margin
- 18.52%
- Trailing P/E
- 29.64
- Forward P/E
- 24.57
- Price/Book (MRQ)
- 2.16
- Price/Sales (TTM)
- 5.46
- EV/EBITDA
- 15.82
- EV/Revenue
- 4.77
- Dividend Yield
- 5.41%
- Book Value
- ¥6.01
- Free Cash Flow (FY2025)
- ¥944.67M
- Free Cash Flow Yield
- 3.97%
Snapshot as of 4th September 2026 — not point-in-time controlled, may lag the live market by a few days.